Leadership team

David P. King is a respected senior healthcare executive who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, and staying ahead of rapidly evolving industry trends and challenges. He uses the insights gained in his 20+ year healthcare career in providing strategic and operational advice to a number of industry stakeholders.

David served for over 13 years as executive chair and CEO of Laboratory Corporation of America Holdings (Labcorp). Under his leadership, Labcorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering the Fortune 500, and being named to Fortune’s List of World’s Most Admired Companies.

In 2019, Forbes named David to its list of America’s Most Innovative Leaders. David’s board service includes non-executive chair of Privia Health (NASDAQ:PRVA) and non- executive chair of ZimVie (NASDAQ:ZIMV). He also serves on a number of private boards.

David’s community service includes board member of Novant Health, a super-regional integrated health system, and advisory board and executive committee member of Duke University’s Robert J. Margolis, MD, Center for Health Policy. David previously served on the board of Cardinal Health (NYSE: CAH), a Fortune 20 healthcare company, and the American Clinical Laboratory Association, where he served as board chair from 2010 to 2014.

David holds a bachelor’s degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School.

Euan was appointed President and Chief Executive Officer in September 2021.

Having initially joined LGC as a Non-Executive Director, a role he filled from 2007 to 2010, Euan took up an Executive role as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012 and building LGC’s wider Quality Assurance business over the following eight years.

Euan has served as an Executive Director on the Board of LGC since 2017 and was appointed President and Chief Operating Officer (COO) in June 2020.

Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan spent the early part of his career in business strategy consulting and corporate finance. Euan is a graduate of University College, Oxford.

Vivid joined LGC as Chief Financial Officer on 24 January 2022, from Tate & Lyle Plc, a global ingredients and solutions company.

Prior to this, he served as CFO of Delphi Technologies Plc and LivaNova Plc and led both companies through their public listings. Earlier in his career, he held senior management positions in Allergan Inc., Gillette Inc., and GlaxoSmithKline Plc in the US, Europe and the Middle East.

Vivid is a member of the Chartered Institute of Management Accountants and holds a Master’s Degree in Finance from the University of Exeter.

Tish joined the Board of LGC in August 2020.

Prior to joining the Group, Tish served as the Execute Vice President of Applied Solutions Strategy, Marketing and Innovation (SMI) for MilliporeSigma, a Merck KGaA Company. Before the acquisition of Sigma-Aldrich by Merck KGaA, Tish was part of Sigma-Aldrich from 2005 – 2015 and served as Vice President of the Diagnostics & Testing team as well as Vice President of the Global Custom Products business focused on oligonucleotides and peptides.

From 1999 to 2005, Tish was with Applied Biosystems serving as Director, R&D Proteomics & Small Molecule Division with a focus on mass spectrometry. Tish has enjoyed a career directing multidisciplinary product development in the life science and pharmaceutical markets and has a successful track record managing in both global multinational environments and small entrepreneurial settings.

Professionally, Tish is the recipient of several scientific achievement awards; she is a published author of both scientific articles and patents. Tish completed her PhD in Organic Chemistry from The Pennsylvania State University, State College, Pennsylvania, USA.

James joined Astorg in 2019 and is a member of the Investment Team. Prior to this, he spent 20 years at ICG where he was Managing Director responsible for investments in the Nordic Region and a member of the Investment Committee.

James started his career at Deloitte where he qualified as a chartered accountant.

James is a graduate of Oxford University.

François joined Astorg in 2012 and is a member of the Investment team.

He has been involved in a number of transactions including Megadyne, Linxens, IQ-EQ, Flowbird, Audiotonix and Anaqua. Prior to joining Astorg, François was with Intermediate Capital Group Plc from 1997. There, he was appointed Managing Director in 2005, then became progressively more responsible for ICG's investment activities in Mezzanine and Equity worldwide. Previously, he was an Associate Director at the LBO division of Société Générale in London and began his career at the M&A division of HSBC in London.

François graduated from the Institut d'Etudes Politiques de Paris and Université de Paris-Dauphine.

Matthew joined Cinven in 2010 and is a member of its Healthcare sector team. He has been involved in a number of transactions, including Medpace, NPS, Pronet, Sebia, STADA, Labco and Synlab (merged under the Synlab brand), Envirotainer and Ufinet.

Prior to joining Cinven, Matthew worked in the Investment Banking Division of Citigroup in London, advising on M&A and restructuring deals across a range of sectors including consumer, real estate, TMT and healthcare.

Matthew graduated from Imperial College London with a Master’s Degree in Physics.

Supraj joined Cinven in 2004 and leads its Healthcare Sector team. He sits on the firm’s Investment and Executive Committees and has worked on a number of transactions, including Ahlsell, Barentz, Bioclinica, CeramTec, JLA, Medpace, National Seating & Mobility, Phadia, Sebia and STADA. 

Prior to joining Cinven, Supraj was at The Boston Consulting Group, where he worked on projects in the healthcare and financial services sectors. 

Supraj graduated from Cambridge University with undergraduate and postgraduate degrees in Medical Sciences. 

Nicolas joined the Board of LGC in April 2016. Prior to joining the Group, Nicolas served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group (2009 to 2013) and Vice President and General Manager of the Life Sciences Division (2006 to 2009).

Prior to joining Agilent Technologies Inc., Nicolas was with Bio-Rad Laboratories, Inc. (2005 to 2006) and served as the Life Science Group’s Group Operations Officer, heading five business divisions spanning life science and food science. His time at Stratagene Corporation (2001 to 2005) saw him serve as Senior Vice President of Marketing, Sales and Business Development for the first two years and then as Chief Operating Officer.

Professionally, Nicolas is currently a Thematic Partner with Summa Equity AB and serves on several public and private BODs.  He also serves as an industry consult to PE firms across the Global Life Science and Diagnostics markets.

Sebastian is a Senior Portfolio Manager in ADIA’s EMEA Private Equity team. Prior to joining ADIA in 2017, he held positions at G Square Healthcare Private Equity Ltd and Rothschild & Co’s Healthcare team in London.

Sebastian holds a Bachelor’s Degree in Physics and Philosophy from Yale University and an MBA from Columbia Business School.

Euan was appointed President and Chief Executive Officer in September 2021.

Having initially joined LGC as a Non-Executive Director, a role he filled from 2007 to 2010, Euan took up an Executive role as Corporate Development Director from July 2010 before being appointed Managing Director of the Standards division in 2012 and building LGC’s wider Quality Assurance business over the following eight years.

Euan has served as an Executive Director on the Board of LGC since 2017 and was appointed President and Chief Operating Officer (COO) in June 2020.

Euan joined LGC from the UK mid-market private equity house LGV Capital, where he was an Investment Director. Prior to that, Euan spent the early part of his career in business strategy consulting and corporate finance. Euan is a graduate of University College, Oxford.

Vivid joined LGC as Chief Financial Officer on 24 January 2022, from Tate & Lyle Plc, a global ingredients and solutions company.

Prior to this, he served as CFO of Delphi Technologies Plc and LivaNova Plc and led both companies through their public listings. Earlier in his career, he held senior management positions in Allergan Inc., Gillette Inc., and GlaxoSmithKline Plc in the US, Europe and the Middle East.

Vivid is a member of the Chartered Institute of Management Accountants and holds a Master’s Degree in Finance from the University of Exeter.

Derek joined the Board of LGC on 1 February 2012 as Chief Scientific Officer.  He continues with his existing role leading LGC's National Measurement Laboratory.

Derek's responsibilities as CSO include leading the scientific efforts of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.

Bharathi joined SeraCare in 2000, which was subsequently acquired by LGC.

Bharathi served as Senior Vice President of Product Development and Technical Operations from 2014 and, in 2021, assumed leadership of LGC Clinical Diagnostics as its Executive Vice President and General Manager.

Prior to joining SeraCare, Bharathi was a lead scientist at DNA Technologies where she developed molecular assays and managed contract manufacturing. She has more than 25 years of experience in technology and product development in infectious diseases, oncology, genetic diseases and recombinant virus.

Bharathi has a PhD in Microbiology from Osmania University, India.

Mark was appointed Managing Director, LGC Biosearch Technologies in July 2020.

Having initially joined LGC as a business unit director in 2011, Mark went on to serve as Vice President of Strategy and Marketing for the Genomics Division. In this role, Mark was responsible for the M&A activities, partnering, organic product development and marketing communications activities.

Prior to joining LGC, Mark held diverse international leadership positions in General management, marketing, product management and sales with leading life sciences companies such as GE Healthcare and Thermo Scientific.  Mark has a Batchelor’s Degree from the University of Sydney and an MBA from Warwick Business School.

Ken joined LGC as Executive Vice President and General Manager, LGC Standards in September 2022.

Prior to joining LGC, Ken co-founded Fortis Life Sciences in 2020 where he served as Chief Operating Officer.  Before Fortis, he held several senior executive roles at MilliporeSigma over the course of 10 years, most recently as the Vice President and Head of the Lab and Specialty Chemicals Business Unit.  Earlier in his career, Ken worked as a management consultant for McKinsey and Company, and as a postdoctoral fellow at the Novartis Institute for Biomedical Research.

Ken graduated with a PhD in Neuroscience from Yale University, and a BS with Honors in Chemistry from Stanford University.

Mike was appointed Senior Vice President, LGC Assure, in January 2022. 

Having joined LGC in 2018, in the roles of Global Head, Ethical Trade and Responsible Sourcing and Director of Global Business Development for BRCGS, Mike was then appointed Business Director, leading Safefood 360˚ following its acquisition in 2020.

Prior to joining LGC, Mike had 20 years in the global Testing, Inspection and Certification (TIC) sector, where he worked for two global businesses and owned his own inspection and auditing firm.

He holds a qualification in Forestry and a certificate in Marketing.

Mehrdad was appointed Executive Vice President and General Manager for LGC Axolabs in July 2023.  Prior to joining LGC, he gained extensive international senior leadership experience in various senior global leadership roles within biopharma and life sciences, including Senior Executive Vice President and Chief Operating Officer for a global corporation focusing on innovative technology in energy materials, chemical, environmental solution, optoelectronics, and oligonucleotide therapeutics & manufacturing.  Mehrdad led therapeutics development teams in the US and Japan, working in partnership with the biotech and pharmaceutical industry. 

Mehrdad also has extensive experience in M&A and post-merger integration, operating and growing global companies, driving efficiency, customer loyalty, and ensuring effective branding and marketing strategies are in place.  Mehrdad has a Ph.D. in Biomedical Engineering, MS in Electrical and Computer Engineering with focus on Modelling and Simulation from the University of California Davis.

Manjeet joined LGC in April 2021 as Chief Digital and Information Officer and was appointed to Chief Transformation Officer (Central Services Group) in July 2022.

Following his service with the Royal Air Force, Manjeet has enjoyed an extensive career in pharmaceuticals with GlaxoSmithKline. He has a wealth of experience in leading global technology functions across the entire pharmaceutical and vaccine verticals. In addition to technology leadership, Manjeet has extensive experience of managing enterprise-wide business transformation programmes.

Manjeet holds a Bachelor’s Degree in Engineering and a Diploma in Accounting and Finance.

Julie joined LGC in August 2022 as Chief People Officer.

During her career, Julie has held a variety of HR leadership roles, including leading the HR functions in Horizon Discovery Plc, Getronics and CPA Global. Julie has both private equity and listed company experience.

Julie holds a Bachelor’s Degree in Ancient History and Archaeology and a Master’s in Contemporary Japan.

Lee originally joined LGC in July 2021 as Chief Technology Officer and was appointed Chief Digital and Information Officer in July 2022.

Prior to joining LGC, Lee worked at Walgreens Boots Alliance (WBA) where he led Global IT Services and Programmes across the organisation’s corporate and retail environments, including supporting retailers’ efforts during the COVID-19 pandemic. Before moving to WBA, Lee had an extensive career working in life sciences at GlaxoSmithKline where he had roles covering infrastructure, enterprise platforms and corporate business services.

Lee holds a Bachelor’s Degree in Business and Computing and a Post Graduate Diploma in Strategy and Innovation from Oxford Saïd Business School.

Greer McMullen joined LGC in September 2020 as General Counsel and Company Secretary.

Greer has a wealth of experience spanning executive roles in a number of companies, including GE, The Service Master Company and most recently Coty Inc. 

Greer has operated across a number of different geographies and cultures, in the Americas, Europe and Asia Pacific. He was educated in the UK and France before attending university in the US at Georgetown University School of Foreign Service and then law school at the University of Virginia School of Law.  He is a member of the Virginia Bar.

Sanjeev joined LGC in 2019 as Finance Director, M&A.

In March 2021, he was appointed to the role of Senior Vice President, Corporate Strategy, Development and Communications and is responsible for the development of enterprise strategy and inorganic growth efforts, as well as overseeing all aspects of investor relations and corporate communications for LGC.

Prior to joining LGC, Sanjeev gained extensive experience in the life sciences, healthcare and industrials sectors, working for international organisations including Hesira Group Limited, Danaher Corporation, UBS Investment Bank and KPMG.

Sanjeev holds a Batchelor’s Degree in Chemistry from the University of East Anglia and is a qualified Chartered Accountant.

Ron Cook is an entrepreneurial scientist focused on the development, application and commercialisation of synthetic nucleic acids. He has a Chemistry degree from UC Berkeley, a PhD from the University of Washington, Seattle, Department of Chemistry, and a post-doctorate from the University of California, San Francisco, Department of Microbiology and Immunology.

Ron founded Biosearch, Inc in 1977 to supply synthetic peptides and protein bioconjugates to the research community. In 1980, the production of synthetic nucleic acids propulsed the company to become a leading innovator in oligonucleotide chemistry and a leader in the supply and technology development for synthetic DNA.  In 1982, the company developed the first commercially viable oligo synthesizer (SAM I), which enabled the invention of PCR in 1983. Over the next 30 years, under Ron’s leadership, Biosearch and its descendent entities, participated in the development of many oligo-driven technologies, including PCR, therapeutic antisense oligos, synthetic gene manufacture, sequencing of the human genome, si-RNA and recently, fluorescent probes for genomic analysis and qPCR.   

Ron has published over 30 scientific papers and issued more than 25 patents. Today, Ron is chairman of a number of organisations in the US, Denmark and Germany. He is also co-founder and chairman of Optical Biosystems.

Duncan is the Research Professor of Chemistry and Head of Department for Pure and Applied Chemistry at the University of Strathclyde in Glasgow. 

Duncan obtained his Batchelor’s Degree and PhD in Chemistry from the University of Edinburgh before joining the University of Strathclyde in 1996. He is Editor in Chief of the RSC journal ‘Analyst’ and serves several editorial advisory boards including ‘Chemical Society Reviews’ and ‘Chemical Science’.

Duncan is President of the analytical division of the Royal Society of Chemistry and Chair of the analytical chemistry trust fund. He has published over 250 papers with 16 patents and has supervised over 60 PhD students and 35 postdoctoral researchers.

Duncan’s scientific interests are in using synthetic chemistry to produce sensors that respond to a specific biological species or events as measured by Raman spectroscopy or SERS. 

Sven provides STRATEGIC consulting services to cell and gene therapy organisations focused on business strategy, R&D, clinical development and commercial planning.

Prior to heading his own consultancy, Sven was VP and Development Head for the Gene and Cell Therapy division of GSK where he led the teams developing ex-vivo gene therapies for a variety of genetic disorders. Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy clinical and medical activities, he oversaw all UK & Ireland regulatory functions and was the QPPV for the EU.

Sven trained as an orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practice, has grown his expertise in all aspects of cell and gene therapy. In addition to his consulting role, he has a number of other roles, including Board member for CCRM in Canada, Board member for Xintela A.B, Visiting Professor and Steering Committee chair for UCL Cell & Gene Therapy MSc and Chair of the BioIndustry Cell & Gene Therapy Advisory Committee. Sven also serves on specialist committees for the SCB, ASGCT and Alliance for Regen Med. He still maintains his clinical skills in the UK NHS and serves as an ATLS instructor in his spare time. 

Alec is a Food Safety Consultant with over 35 years experience in the food industry, most recently as Head of Technical Operations at the retailer Sainsbury’s.

Alec is a microbiologist, graduating from Surrey University and prior to his 28 years with Sainsbury's, where he was responsible for safety and quality management, he worked in manufacturing including the brewing, dairy and food sectors.

Alec is currently a Non Executive Board Director of CampdenBRI, a Trustee of the Institute of Food Science and Technology, a Member of the Advisory Committee on the Microbiological Safety of Food, Chair of the BRCGS International Advisory Board and a visiting lecturer at Queen’s University Belfast.

Alec’s interests are in food safety and quality assurance frameworks and he is the co-author of books on the practical control of food borne pathogens including Salmonella, Listeria, C. botulinum, Campylobacter and E. coli.

Gene is an expert in the areas of RNA biology and therapeutics, computational biology, genomics and neurological diseases.

He is a Professor of Cellular and Molecular Medicine at the University of California, San Diego (UCSD). He has Batchelor’s Degrees in Chemical Engineering and in Economics from the University of Illinois, Urbana-Champaign, a PhD in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management.

Gene’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders and developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions. Gene’s lab is an active participant in RNA genomics technology and therapeutics development.

Gene is on the editorial boards of the journals ‘Cell Reports’ and ‘Cell Research’. He is a recipient of the Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017).

Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. He serves or has served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.

Derek joined the Board of LGC on 1 February 2012 as Chief Scientific Officer.  He continues with his existing role leading LGC's National Measurement Laboratory.

Derek's responsibilities as CSO include leading the scientific efforts of the company, coordinating science development across the business and developing our scientific partnerships for research, discovery and innovation. Derek was Government Chemist from June 2008 - May 2018.